Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan with Carboplatin and Serplulimab in ES-SCLC
NCT06462105Phase 2Not yet recruiting
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of irinotecan liposome in small cell lung cancer (SCLC) (2 arms). Primary endpoint: Progression-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06462105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462105.